Retinal Vessel Diameter in Branch Retinal Vein Occlusion
NCT ID: NCT02215109
Last Updated: 2016-08-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
25 participants
OBSERVATIONAL
2012-04-30
2016-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Major and Macular Branched Retinal Venous Occlusion
NCT01219205
Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study
NCT02015351
Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy
NCT00383812
Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy
NCT00423059
Bevacizumab Intravitreal for Myopic Choroidal Neovascularization
NCT00797992
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BRVO, Retinal vessel diameter
The retinal vessel diameter was measured Branch Retinal Vein Occlusion patients after intravitreal bevacizumab injection.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Central subfield macular thickness (CSMT) 300 μm or greater on spectral-domain optical coherence tomography
Exclusion Criteria
* History of previous treatments for BRVO including vitreoretinal surgery, intravitreal injection, subtenon injection or laser photocoagulation
* Patients with diabetes or dyslipidemia
* IOP ≥ 22mmHg, treatment for glaucoma, a family history of glaucoma, or optic neuropathy
* High myopia (\<-6 Diopters), high hyperopia (\>6 Diopters) or a history of refractive surgeries
* Co-existing retinal disease other than BRVO
* Corneal diseases include ulcer, keratoconus and a history of corneal laceration
* Cataract and other media opacities resulting in visual impairment or poor fundus images
40 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kyungpook National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dong Ho Park
Clinical professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dong Ho Park, M.D.
Role: PRINCIPAL_INVESTIGATOR
Kyungpook National University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dong Ho Park
Daegu, Kyungsangpookdo, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KNUHOPH2014-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.